Applying Competitive Intelligence to Navigate the Changing Disease Landscape
In preparation for the 2017 BIO International Convention, Clarivate Analytics and BIO have teamed up to offer this free webinar where we will use neurodegenerative disease as a use case to demonstrate the critical information and analysis needed to be first in class and/or best in class for a therapy area.
David Dunn, US Practice Lead and Scientific Advisor for Portfolio and Licensing, Clarivate Analyticswill analyze the pipelines of three leading neurodegenerative diseases: Alzheimer’s, Parkinson’s and ALS. In this webinar David will examine current therapeutic hypotheses and the industry’s track record in finding therapies based on them.
Cortellis Deals Landscape Q4 2016
During the 4th quarter of 2016, Cortellis Competitive Intelligence had 889 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was an increase on both the last quarter (865) but a decrease from the same quarter for the previous year (915). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestones, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter’s pharmaceutical licensing activity. Click here to read the report.
ON SITE PRESENTATION:
State of the Innovation Industry
This session will feature two presentations on investment and deal-making in the life sciences followed by Q&A. BIO's David Thomas, Senior Director of Industry Research, will present emerging therapeutic company trends across venture funding and public investment (IPOs and follow-ons), as well as small company contributions to the global clinical pipeline and recent drug approvals.
Richard Harrison, Chief Scientific Officer at Clarivate, will provide a detailed account of current licensing and M&A trends across the biopharma sector. Industry experts will debate the drivers behind the recent data presented during the session.
BIO One-on-One Partnering™ is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.
You can invite companies and accept invitations to meet, and once your meetings are mutually accepted, BIO does the scheduling so you arrive to BIO with a plan! Partnering is now open.
Partnering Priorities: Do your homework, tell your story
Four biopharma executives talk about their approach to partnering – how they prepare for a meeting like the BIO International Convention, what they are looking for when they engage with potential partners and investors, what’s next for their companies.
With recent breakthroughs in disease research, it is critical for organizations to have immediate insight into the clinical, regulatory, competitive, and dealmaking challenges as they advance towards commercialization.
This understanding of the disease landscape for your domains of interest is crucial for successful meetings.
Click here to meet the speakers, read the full abstract, and obtain a link to the recording and a copy of the presentation slides.
ADDITION ON SITE PRESENTATIONS:
Summit Brasil is being organized by one of our Brazilian partners (Abiquifi) and is dedicated to Clarivate's LatAm clients. Scheduled to take place Monday June 19th, 2017 at 8:30 AM PST in the Sanford Consortium for Regenerative Medicine. Click here to inquire more information about this session.
ON SITE PRESENTATION:
Russian Delegation Panel
The pharmaceutical industry has faced enormous pressures over the last few decades. Declining revenues, increasing payer pressures, and a constantly changing regulatory landscape have forced all companies to identify processes to increase innovation. However, to date, no one agrees on precisely how to measure innovation or how to interpret these results to understand the state of the industry. This presentation will examine and compare previous attempts to measure the state of innovation in the pharmaceutical industry and combine the best aspects of previous attempts to calculate quantitative measures of innovation.
Richard Harrison is confirmed to speak on this panel, but date, time, and location have yet to be confirmed. Check back for updates.
The BIO International Convention (BIO) annually attracts over 16,000 biotech and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.
How do you ensure you have the necessary clinical, regulatory, and competitive landscape information around your specific therapy area to guarantee informed conversations with potential partners?
Click here to request a meeting with us on site at BIO